MetLife Investment Management LLC Has $3.31 Million Stock Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)

MetLife Investment Management LLC increased its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 82.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 9,900 shares of the medical research company's stock after purchasing an additional 4,478 shares during the period. MetLife Investment Management LLC's holdings in Bio-Rad Laboratories were worth $3,312,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. Capital Advisors Ltd. LLC raised its position in Bio-Rad Laboratories by 193.8% in the second quarter. Capital Advisors Ltd. LLC now owns 94 shares of the medical research company's stock valued at $26,000 after purchasing an additional 62 shares during the period. UMB Bank n.a. grew its stake in shares of Bio-Rad Laboratories by 140.6% during the third quarter. UMB Bank n.a. now owns 77 shares of the medical research company's stock valued at $26,000 after acquiring an additional 45 shares in the last quarter. Gladius Capital Management LP purchased a new stake in shares of Bio-Rad Laboratories during the third quarter worth about $32,000. Headlands Technologies LLC acquired a new position in shares of Bio-Rad Laboratories in the second quarter worth about $51,000. Finally, Quarry LP purchased a new position in Bio-Rad Laboratories in the second quarter valued at about $59,000. 65.24% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

BIO has been the subject of several research analyst reports. Wells Fargo & Company initiated coverage on Bio-Rad Laboratories in a research note on Tuesday, August 27th. They set an "equal weight" rating and a $340.00 target price for the company. StockNews.com raised shares of Bio-Rad Laboratories from a "hold" rating to a "buy" rating in a research report on Friday, November 1st. Royal Bank of Canada boosted their price objective on Bio-Rad Laboratories from $446.00 to $469.00 and gave the company an "outperform" rating in a report on Thursday, October 31st. Finally, Citigroup increased their target price on Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a "buy" rating in a report on Thursday, October 31st. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $391.80.

Insider Activity

In other Bio-Rad Laboratories news, COO Andrew J. Last sold 3,000 shares of the company's stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $329.94, for a total value of $989,820.00. Following the completion of the sale, the chief operating officer now directly owns 7,559 shares of the company's stock, valued at approximately $2,494,016.46. This represents a 28.41 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 17.50% of the company's stock.

Bio-Rad Laboratories Stock Performance

NYSE:BIO traded up $5.80 during mid-day trading on Wednesday, hitting $338.08. The stock had a trading volume of 188,920 shares, compared to its average volume of 243,365. The company has a 50 day simple moving average of $341.10 and a 200-day simple moving average of $318.62. Bio-Rad Laboratories, Inc. has a 52 week low of $262.12 and a 52 week high of $387.99. The stock has a market capitalization of $9.47 billion, a price-to-earnings ratio of -12.16 and a beta of 0.90. The company has a current ratio of 6.14, a quick ratio of 4.52 and a debt-to-equity ratio of 0.16.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last announced its earnings results on Wednesday, October 30th. The medical research company reported $2.01 earnings per share for the quarter, beating the consensus estimate of $1.16 by $0.85. The firm had revenue of $649.70 million for the quarter, compared to the consensus estimate of $628.18 million. Bio-Rad Laboratories had a positive return on equity of 3.74% and a negative net margin of 30.18%. The firm's revenue for the quarter was up 2.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.33 EPS. On average, research analysts expect that Bio-Rad Laboratories, Inc. will post 10.29 earnings per share for the current fiscal year.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.